SCHEMBL10066976

SCHEMBL10066976

CN(C)CCOc1ccccc1C(=O)Nc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.64
SGMS2 Q8NHU3 1/20 0.62
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
BRPF1 P55201 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
NPSR1 Q6W5P4 2/20 0.56
POLB P06746 1/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
RAB9A P51151 1/20 0.55
GAA P10253 1/20 0.54
PKM P14618 1/20 0.54
MAPT P10636 3/20 0.54
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salverine SCHEMBL29360867 0.86 ALDH1A1 (0.70) SGMS2MEN1KMT2ASMN1; SMN2CYP1A2
Salverine SCHEMBL25064 0.86 ALDH1A1 (0.70) SGMS2MEN1KMT2ASMN1; SMN2CYP1A2
Salverine SCHEMBL29375616 0.85 ALDH1A1 (0.68) SGMS2MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL23861119 0.85 GPR27 (0.53) RXFP1SGMS2KMT2ABRPF1SMN1; SMN2
SCHEMBL4753614 0.84 ALDH1A1 (0.54) RXFP1MEN1KMT2ABRPF1SMN1; SMN2
SCHEMBL15529774 0.84 RXFP1 (0.90) RXFP1CYP1A2CYP3A4CYP2C19MAPT
SCHEMBL28661611 0.82 SGMS2 (0.68) SGMS2MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL3453978 0.82 ALDH1A1 (0.65) KMT2ASMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL6669660 0.82 ALDH1A1 (0.68) SMN1; SMN2KDM4EALDH1A1MAPTLMNA
SCHEMBL19799126 0.82 RXFP1 (0.57) RXFP1MEN1KMT2ABRPF1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165813-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-06-01 US disclosed
US-20230165813-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-06-01 US disclosed
US-20210317074-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2021-10-14 US disclosed
US-11034647-B2 Histone acetyltransferase activators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-06-15 US disclosed
US-20200330410-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-10-22 US disclosed
EP-3323813-B1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF UNIV COLUMBIA (US) 2020-08-26 EP disclosed
US-10653648-B2 Histone acetyltransferase activators and compositions and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-19 US disclosed
US-10640457-B2 Histone acetyltransferase activators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-05 US disclosed
US-20200115325-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-04-16 US disclosed
EP-3323813-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2018-05-23 EP disclosed
US-9969677-B2 Histone acetyltransferase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-05-15 US disclosed
US-20180021273-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2018-01-25 US disclosed
US-20180021273-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2018-01-25 US disclosed
WO-2018017858-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-01-25 WO disclosed
US-20170121276-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-04 US disclosed
US-20170121276-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-04 US disclosed
US-20130121919-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-05-16 US disclosed
US-20130121919-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-05-16 US disclosed
WO-2012088420-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USESE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-06-28 WO disclosed
WO-2011072243-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034647-B2 Histone acetyltransferase activators and uses thereof EP300, KAT2A, NAA40 RXFP1 4561/4885SGMS2 2431/4885MEN1 2361/4885
US-20180021273-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF HDAC6, HDAC9, HDAC5 RXFP1 4599/4885SGMS2 1205/4885MEN1 3547/4885
US-20200115325-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF EP300, KAT2A, NAA40 RXFP1 4561/4885SGMS2 2431/4885MEN1 2361/4885
US-10640457-B2 Histone acetyltransferase activators and uses thereof EP300, KAT2A, NAA40 RXFP1 4561/4885SGMS2 2431/4885MEN1 2361/4885
US-20170121276-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF EP300, KAT2A, HTT RXFP1 4586/4885SGMS2 819/4885MEN1 2596/4885
US-20210317074-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF EP300, KAT2A, NAA40 RXFP1 4561/4885SGMS2 2431/4885MEN1 2361/4885
US-20200330410-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF HDAC6, HDAC9, HDAC5 RXFP1 4599/4885SGMS2 1205/4885MEN1 3547/4885
US-10653648-B2 Histone acetyltransferase activators and compositions and uses thereof HDAC6, HDAC9, HDAC5 RXFP1 4599/4885SGMS2 1205/4885MEN1 3547/4885
US-20130121919-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF EP300, KAT2A, NAA40 RXFP1 4561/4885SGMS2 2431/4885MEN1 2361/4885
US-20230165813-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF HDAC6, HDAC9, HDAC5 RXFP1 4599/4885SGMS2 1205/4885MEN1 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.